Lilly’s Covid-19 antibody looks promising in early data
In the first major test of antibody treatments for Covid-19, a drug from Eli Lilly helped sick patients rid their systems of the virus sooner and reduced the hospitalization rate compared to placebo.
According to interim data from an ongoing trial, one dose of Lilly’s antibody met the trial’s primary goal of significantly reducing patients’ levels of SARS-CoV-2 after 11 days. Two other doses, including a higher one, did not meet that goal. More promisingly, just 1.7% of patients who received any dose of Lilly’s treatment were eventually hospitalized, compared with 6% of those who took placebo, amounting to 72% relative reduction in risk.
The results are preliminary, have yet to be peer reviewed. But they are the best evidence yet that custom-built antibodies may prove effective against Covid-19.
Read more.
According to interim data from an ongoing trial, one dose of Lilly’s antibody met the trial’s primary goal of significantly reducing patients’ levels of SARS-CoV-2 after 11 days. Two other doses, including a higher one, did not meet that goal. More promisingly, just 1.7% of patients who received any dose of Lilly’s treatment were eventually hospitalized, compared with 6% of those who took placebo, amounting to 72% relative reduction in risk.
The results are preliminary, have yet to be peer reviewed. But they are the best evidence yet that custom-built antibodies may prove effective against Covid-19.
Read more.
.png)
No hay comentarios:
Publicar un comentario